Connection

Robert Grubb to Prostatic Neoplasms

Back to Details
This is a "connection" page, showing publications Robert Grubb has written about Prostatic Neoplasms.
Robert Grubb
Connection Strength
6.108
Prostatic Neoplasms
  1. Editorial Comment. J Urol. 2019 04; 201(4):740-741.
    View in: PubMed
    Score: 0.421
  2. Prostate Cancer: Update on Early Detection and New Biomarkers. Mo Med. 2018 Mar-Apr; 115(2):132-134.
    View in: PubMed
    Score: 0.391
  3. Screening for cancer: lessons learned from the prostate, lung, colorectal, and ovarian cancer screening trial. Eur Urol. 2015 Oct; 68(4):545-6.
    View in: PubMed
    Score: 0.321
  4. The REDUCE Follow-Up Study: low rate of new prostate cancer diagnoses observed during a 2-year, observational, followup study of men who participated in the REDUCE trial. J Urol. 2013 Mar; 189(3):871-7.
    View in: PubMed
    Score: 0.268
  5. High-risk localized prostate cancer: role of radical prostatectomy. Curr Opin Urol. 2010 May; 20(3):204-10.
    View in: PubMed
    Score: 0.227
  6. Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. J Proteome Res. 2009 Jun; 8(6):3044-54.
    View in: PubMed
    Score: 0.213
  7. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int. 2008 Dec; 102(11):1524-30.
    View in: PubMed
    Score: 0.206
  8. The effect of body mass index on PSA levels and the development, screening and treatment of prostate cancer. Nat Clin Pract Urol. 2007 Nov; 4(11):605-14.
    View in: PubMed
    Score: 0.191
  9. High-grade prostate cancer in the Prostate Cancer Prevention Trial: fact or artifact? J Natl Cancer Inst. 2007 Sep 19; 99(18):1355-6.
    View in: PubMed
    Score: 0.189
  10. Prostate cancer: screening, diagnosis and management in 2007. Mo Med. 2007 Sep-Oct; 104(5):408-13; quiz 413-4.
    View in: PubMed
    Score: 0.189
  11. Minimally invasive approaches to localized prostate carcinoma. Hematol Oncol Clin North Am. 2006 Aug; 20(4):879-95.
    View in: PubMed
    Score: 0.175
  12. Can preoperative PSA doubling time and PSA velocity predict outcomes following radical prostatectomy? Nat Clin Pract Urol. 2006 Jun; 3(6):306-7.
    View in: PubMed
    Score: 0.173
  13. Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics. 2003 Nov; 3(11):2142-6.
    View in: PubMed
    Score: 0.145
  14. Decision aids for localized prostate cancer in diverse minority men: Primary outcome results from a multicenter cancer care delivery trial (Alliance A191402CD). Cancer. 2022 03 15; 128(6):1242-1251.
    View in: PubMed
    Score: 0.127
  15. Improved survival with post-diagnostic metformin and statin use in a racially diverse cohort of US Veterans with advanced prostate cancer. Prostate Cancer Prostatic Dis. 2022 Apr; 25(4):707-712.
    View in: PubMed
    Score: 0.126
  16. One-year urinary and sexual outcome trajectories among prostate cancer patients treated by radical prostatectomy: a prospective study. BMC Urol. 2021 May 17; 21(1):81.
    View in: PubMed
    Score: 0.122
  17. Risk of Prostate Cancer-related Death Following a Low PSA Level in the PLCO Trial. Cancer Prev Res (Phila). 2020 04; 13(4):367-376.
    View in: PubMed
    Score: 0.112
  18. The association of marital status and mortality among men with early-stage prostate cancer treated with radical prostatectomy: insight into post-prostatectomy survival strategies. Cancer Causes Control. 2019 Aug; 30(8):871-876.
    View in: PubMed
    Score: 0.107
  19. Self-Management in Long-Term Prostate Cancer Survivors: A Randomized, Controlled Trial. J Clin Oncol. 2019 05 20; 37(15):1326-1335.
    View in: PubMed
    Score: 0.105
  20. Levels and patterns of self-reported and objectively-measured free-living physical activity among prostate cancer survivors: A prospective cohort study. Cancer. 2019 03 01; 125(5):798-806.
    View in: PubMed
    Score: 0.103
  21. Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial. BJU Int. 2019 05; 123(5):854-860.
    View in: PubMed
    Score: 0.102
  22. The comparative effectiveness of decision aids in diverse populations with early stage prostate cancer: a study protocol for a cluster-randomized controlled trial in the NCI Community Oncology Research Program (NCORP), Alliance A191402CD. BMC Cancer. 2018 Aug 06; 18(1):788.
    View in: PubMed
    Score: 0.101
  23. Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy. Eur Urol Oncol. 2018 06; 1(2):143-148.
    View in: PubMed
    Score: 0.099
  24. Prostate Magnetic Resonance Imaging Provides Limited Incremental Value Over the Memorial Sloan Kettering Cancer Center Preradical Prostatectomy Nomogram. Urology. 2018 03; 113:119-128.
    View in: PubMed
    Score: 0.096
  25. Caution with Use of the EPIC-50 Urinary Bother Scale: How Voiding Dysfunction Modifies its Performance. J Urol. 2017 12; 198(6):1397-1403.
    View in: PubMed
    Score: 0.094
  26. Trichomonas vaginalis infection and risk of prostate cancer: associations by disease aggressiveness and race/ethnicity in the PLCO Trial. Cancer Causes Control. 2017 Aug; 28(8):889-898.
    View in: PubMed
    Score: 0.093
  27. Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial. Trials. 2017 04 18; 18(1):181.
    View in: PubMed
    Score: 0.092
  28. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017 Feb 15; 123(4):592-599.
    View in: PubMed
    Score: 0.090
  29. Determination of the Role of Negative Magnetic Resonance Imaging of the Prostate in Clinical Practice: Is Biopsy Still Necessary? Urology. 2017 04; 102:190-197.
    View in: PubMed
    Score: 0.089
  30. Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States. J Urol. 2016 Oct; 196(4):1096-104.
    View in: PubMed
    Score: 0.087
  31. Earlier prostate-specific antigen testing in African American men--Clinical support for the recommendation. Urol Oncol. 2015 Jul; 33(7):330.e9-17.
    View in: PubMed
    Score: 0.080
  32. Sex steroid hormone metabolism in relation to risk of aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014 Nov; 23(11):2374-82.
    View in: PubMed
    Score: 0.077
  33. Evaluation of 3 T pelvic MRI imaging in prostate cancer patients receiving post-prostatectomy IMRT. World J Urol. 2015 Jan; 33(1):69-75.
    View in: PubMed
    Score: 0.074
  34. Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer. 2013 Jun 15; 119(12):2223-9.
    View in: PubMed
    Score: 0.070
  35. Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans? Urol Oncol. 2014 Jan; 32(1):34.e9-18.
    View in: PubMed
    Score: 0.069
  36. Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol. 2013 Sep; 64(3):372-8.
    View in: PubMed
    Score: 0.069
  37. Prostate cancer specific survival in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer Epidemiol. 2012 Dec; 36(6):e401-6.
    View in: PubMed
    Score: 0.067
  38. Projecting prostate cancer mortality in the PCPT and REDUCE chemoprevention trials. Cancer. 2013 Feb 01; 119(3):593-601.
    View in: PubMed
    Score: 0.067
  39. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012 Jan 18; 104(2):125-32.
    View in: PubMed
    Score: 0.064
  40. Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol. 2011 Feb 01; 29(4):355-61.
    View in: PubMed
    Score: 0.059
  41. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009 Mar 26; 360(13):1310-9.
    View in: PubMed
    Score: 0.053
  42. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2009 Mar; 18(3):748-51.
    View in: PubMed
    Score: 0.052
  43. Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control. 2008 Dec; 19(10):1267-76.
    View in: PubMed
    Score: 0.050
  44. Patient selection determines the prostate cancer yield of dynamic contrast-enhanced magnetic resonance imaging-guided transrectal biopsies in a closed 3-Tesla scanner. BJU Int. 2008 Jan; 101(2):181-5.
    View in: PubMed
    Score: 0.048
  45. Magnetic resonance imaging-directed transrectal ultrasonography-guided biopsies in patients at risk of prostate cancer. BJU Int. 2007 May; 99(5):1041-6.
    View in: PubMed
    Score: 0.046
  46. Prostate-specific antigen velocity and prostate cancer gleason grade and stage. Cancer. 2007 Apr 15; 109(8):1689-95.
    View in: PubMed
    Score: 0.046
  47. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial. BJU Int. 2007 Apr; 99(4):775-9.
    View in: PubMed
    Score: 0.045
  48. Highlights from the Society of Urologic Oncology, 5th Annual Meeting, December 3-4, 2004, Bethesda, Maryland, United States of America. J Urol. 2005 Dec; 174(6):2330-3.
    View in: PubMed
    Score: 0.042
  49. Results of compliance with prostate cancer screening guidelines. J Urol. 2005 Aug; 174(2):668-72; discussion 672.
    View in: PubMed
    Score: 0.041
  50. Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml. J Urol. 2005 Apr; 173(4):1116-20.
    View in: PubMed
    Score: 0.040
  51. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst. 2005 Mar 16; 97(6):433-8.
    View in: PubMed
    Score: 0.040
  52. An interventional magnetic resonance imaging technique for the molecular characterization of intraprostatic dynamic contrast enhancement. Mol Imaging. 2005 Jan-Mar; 4(1):63-6.
    View in: PubMed
    Score: 0.039
  53. Predicting risk of bladder cancer using clinical and demographic information from prostate, lung, colorectal, and ovarian cancer screening trial participants. Cancer Epidemiol Biomarkers Prev. 2013 Dec; 22(12):2241-9.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.